Track TBPH and 10,000+ stocks
Create a free account to build watchlists, compare peers, and value any stock.
- Build and track watchlists
- Compare against peers
- Earnings & price alerts
No credit card required
Theravance Biopharma Inc
901 Gateway Boulevard, South San Francisco, CA, United States, 94080
IPO
2014
Employees
90
Industry
Biotechnology
Sector
Healthcare
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
Insider Transactions
Quarterly buy vs. sell activity
Sell (left)Buy (right)
Q1 20261-1
0
Q4 20251-1
0
Q3 20252-2
0
Q2 20251-1
0
4-quarter cumulative
5 sells0 buys
Analyst Ratings
3 analysts covering
Hold67%recommend hold
Buy
1
Hold
2
Sell
0